PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18268399-11	2008	CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL.	Chromium	82-84	keratin 20	Homo sapiens	103-107	
11067958-2	2000	In (51)Cr release assays with whole blood as effector source, RAJI cells were effectively killed by a mouse/human chimeric IgG1 construct of CD20 Ab 1F5, whereas ARH-77 proved resistant to killing by this Ab.	Chromium	7-9	keratin 20	Homo sapiens	141-145	
9672771-6	1998	Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made.	Chromium	21-23	keratin 20	Homo sapiens	88-92	
9672771-6	1998	Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made.	Chromium	116-118	keratin 20	Homo sapiens	88-92	
29534755-7	2018	CD20+ B lymphocytes represented 14.9% in the dnIH group and 29.1% in the CR group.	Chromium	73-75	keratin 20	Homo sapiens	0-4	
16128896-13	2005	The anti-CD20 monoclonal antibody rituximab was given to two patients in conventional doses and a CR was seen in one patient.	Chromium	98-100	keratin 20	Homo sapiens	9-13	
24490292-6	2013	RESULT: Patients with CRS had higher infiltration of the B lymphocytes (CD20) and T lymphocyte subsets (CD4, CD88) than the patients of the control group (P < 0.05).	Chromium	22-25	keratin 20	Homo sapiens	72-76